ASCLETIS-B (01672) reported the latest breakthrough research on the novel fatty acid synthase (FASN) inhibitor Dehexastat (ASC40) for the treatment of acne in a dedicated session at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting.

ASCLETIS-B (01672) announced that at the 2025 European Academy of Dermatology and Venereology (EADV) Annual Meeting, held in Paris, France on September 17, 2025, they presented the latest breakthrough research on denifanstat (ASC40) for the treatment of moderate to severe acne in phase III study (NCT06192264). "Denifanstat (ASC40) is an innovative therapy in the field of acne treatment, with potential clinical significance. We are honored to present these results to the dermatology community at this year's EADV conference," said Dr. Wu Jinzi, founder, chairman, and CEO of ASCLETIS. "Denifanstat (ASC40) utilizes a novel mechanism of action for acne treatment, and in the phase III study, all primary and secondary endpoints showed statistically significant and clinically meaningful improvements compared to placebo, while also demonstrating good safety and tolerability." ASCLETIS is in pre-New Drug Application (NDA) communication with the China National Medical Products Administration (NMPA) for denifanstat (ASC40), and has received positive feedback from NMPA. After completing the pre-NDA communication, ASCLETIS plans to submit an NDA to NMPA for the marketing approval of denifanstat (ASC40) for the treatment of moderate to severe acne. ASCLETIS has obtained exclusive rights for denifanstat (ASC40) in Greater China from Sagimet Biosciences Inc. (NASDAQ: SGMT).